Editas Medicine, Inc.

EDIT

US28106W1036

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-05 EDT			5-day change	1st Jan Change
4.59 ^USD	-1.50%		-1.71%	-54.69%

06-27	Editas Medicine, Inc. Announces Resignation of Akshay Vaishnaw from the Board Effective as of June 30, 2024	CI
06-14	Editas Medicine Says Its Gene Editing Potential Treatment for Sickle-Cell Disease Found Well-Tolerated in Phase 1/2 Trial	MT

Editas Medicine, Inc. Announces Resignation of Akshay Vaishnaw from the Board Effective as of June 30, 2024

June 27, 2024 at 05:03 pm

On June 27, 2024, Akshay Vaishnaw informed the Board of Directors (the Board) of Editas Medicine, Inc. (the Company) of his resignation from the Board effective as of June 30, 2024.

Latest news about Editas Medicine, Inc.

Editas Medicine, Inc. Announces Resignation of Akshay Vaishnaw from the Board Effective as of June 30, 2024	06-27	CI
Editas Medicine Says Its Gene Editing Potential Treatment for Sickle-Cell Disease Found Well-Tolerated in Phase 1/2 Trial	06-14	MT
Editas Medicine, Inc. Reports New Safety and Efficacy Data from the Rubber Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association Annual Congress	06-14	CI
Editas Medicine Announces New Safety and Efficacy Data from the Edithal Trial of Reni-Cel in 7 Patients with Transfusion-Dependent Beta Thalassemia, Presented At the European Hematology Association Annual Congress	06-14	CI
Evercore ISI Cuts Price Target on Editas Medicine to $7 From $15, Maintains In Line Rating	05-30	MT
Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing	05-14	MT
Barclays Adjusts Editas Medicine Price Target to $9 From $11, Maintains Equal Weight Rating	05-09	MT
Morgan Stanley Upgrades Editas Medicine to Equal-Weight From Underweight	05-09	MT
Transcript : Editas Medicine, Inc., Q1 2024 Earnings Call, May 08, 2024	05-08
Editas Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration	05-01	MT
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration	05-01	CI
Transcript : Editas Medicine, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:05 PM	03-13
Barclays Adjusts Price Target on Editas Medicine to $11 From $10, Maintains Equal-Weight Rating	02-29	MT
Transcript : Editas Medicine, Inc., Q4 2023 Earnings Call, Feb 28, 2024	02-28
Editas Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Editas Medicine, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-28	CI
North American Morning Briefing : Stock Futures -2-	02-21	DJ
Transcript : Editas Medicine, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 04:30 PM	01-09
RBC Boosts Price Target on Editas Medicine to $11 From $8, Keeps Sector Perform Rating	01-03	MT
Editas Medicine Strikes License Deal With Vertex Pharmaceuticals -- Update	12-13	DJ
Editas Medicine Enters Licensing Deal With Vertex Pharmaceuticals for Cas9	12-13	MT
Editas Medicine Strikes License Deal With Vertex Pharmaceuticals	12-13	DJ
Editas Medicine and Vertex Pharmaceuticals Enter into Non-Exclusive License Agreement for Cas9	12-13	CI
Truist Adjusts Editas Medicine's Price Target to $20 From $15, Maintains Buy Rating	12-12	MT

Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).

Sector

Biotechnology & Medical Research

Calendar

2024-07-30 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Editas Medicine, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4.59 USD

Average target price

14.47 USD

Spread / Average Target

+215.18%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EDITAS MEDICINE, INC.	-54.69%	377M
MODERNA, INC.	+18.97%	45.34B
LONZA GROUP AG	+41.98%	40.42B
IQVIA HOLDINGS INC.	-10.06%	37.92B
ALNYLAM PHARMACEUTICALS, INC.	+31.15%	31.75B
CELLTRION, INC.	-7.79%	27.71B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.52B
UNITED THERAPEUTICS CORPORATION	+43.05%	13.96B
MEDPACE HOLDINGS, INC.	+31.28%	12.44B
BIO-TECHNE CORPORATION	-7.41%	11.26B

Other Biotechnology & Medical Research